Mosunetuzumab

SAN DIEGO — In this video, Paolo Caimi, MD, a physician and clinical investigator at Cleveland Clinic, discussed research on the use of bispecific antibodies for lymphoma presented at ASH Annual Meeting and Exposition.

More than 20% of reported cases of adverse events following bispecific T-cell engager therapies involved a cardiovascular event, findings reported in Journal for ImmunoTherapy of Cancer showed.

SAN DIEGO — Subcutaneous time-limited mosunetuzumab exhibited “highly encouraging efficacy” among patients with newly diagnosed high-burden follicular lymphoma, according to researchers.

NEW ORLEANS — Mosunetuzumab with polatuzumab vedotin showed efficacy in patients with diffuse large B-cell lymphoma who are younger and older than 65 years, according to research presented at the ASH Annual Meeting and Exhibition.

Healio spoke with Joshua Brody, MD, about unmet needs and distinct challenges, as well as the treatment landscape in diffuse large B-cell lymphoma.

The FDA granted accelerated approval to mosunetuzumab-axgb for treatment of adults with relapsed or refractory follicular lymphoma, the agency announced in a press release.

The FDA granted priority review to mosunetuzumab for treatment of certain patients with relapsed or refractory follicular lymphoma.

Mosunetuzumab more than quadrupled the complete response rate among patients with relapsed or refractory follicular lymphoma, according to results of a pivotal phase 2 study.

ORLANDO — About 20% of a cohort of patients with aggressive relapsed or refractory non-Hodgkin lymphoma experienced complete response to treatment with the investigational agent mosunetuzumab, according to updated data from a phase 1/phase 1b dose-escalation and dose-expansion study presented during the plenary session of ASH Annual Meeting and Exposition.

In this video, Joshua Brody, MD, director of the lymphoma immunotherapy program at Tisch Cancer Institute at Mount Sinai, discusses the impact the approval of mosunetuzumab has had on the treatment of follicular lymphoma.